Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alterity Therapeutics Ltd
ATHCurrent price
0.003 AUD
+0.000000000077 AUD (+0.00%)
Last closed
1.07 USD
Company
alteritytherapeutics.com
ISIN
US02155X1063
Sector
Healthcare
Industry
Biotechnology
Exchange
Australian Securities Exchange
Capitalization
10 158 718 USD
Yield for 12 month
-42.16 %
1Y
3Y
5Y
10Y
15Y
ATH
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
+1 742 143 USD
Last Year
+1 695 032 USD
Current Quarter
+459 141 USD
Last Quarter
+448 842 USD
Current Year
+1 679 323 USD
Last Year
+1 628 579 USD
Current Quarter
+427 659 USD
Last Quarter
+423 983 USD
Key Figures ATH
1 year
3 years
5 years
10 years
EBITDA
-19 571 604 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.66 %
PEG Ratio
–
Return On Equity TTM
-104.47 %
Wall Street Target Price
7 USD
Revenue TTM
4 019 285 USD
Book Value
0.003 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
38.4 %
Dividend Yield
–
Gross Profit TTM
3 631 266 USD
Earnings per share
-1.94 USD
Diluted Eps TTM
-1.94 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.01.2023
Dividend Date
–
Stock Valuation ATH
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
113.9898
Price Sales TTM
2.5275
Enterprise Value EBITDA
0.7546
Price Book MRQ
1.0785
Financials ATH
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATH
For 52 weeks
1.01 USD
5.41 USD
50 Day MA
1.24 USD
Shares Short Prior Month
6 216
200 Day MA
1.68 USD
Short Ratio
0.32
Shares Short
3 574
Short Percent
0.04 %
BeatStart